Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Coherus Oncology's enterprise value is €122.06 Mil.
Coherus Oncology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-127.50 Mil. Therefore, Coherus Oncology's EV-to-EBITDA for today is -0.96.
The historical rank and industry rank for Coherus Oncology's EV-to-EBITDA or its related term are showing as below:
FRA:8C5'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.64 Med: -3.22 Max: 229
Current: -0.95
During the past 13 years, the highest EV-to-EBITDA of Coherus Oncology was 229.00. The lowest was -23.64. And the median was -3.22.
FRA:8C5's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 13.6
vs FRA:8C5: -0.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Coherus Oncology's PE Ratio (TTM) for today is calculated as:
Coherus Oncology's share price for today is €1.03.
Coherus Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.884.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Coherus Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs NAUT, AVXL, SLNCF: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Coherus Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's EV-to-EBITDA falls into.
Coherus Oncology's current Enterprise Value is €122.06 Mil.
Coherus Oncology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-127.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (FRA:8C5) has a EV-to-EBITDA of -0.96 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Coherus Oncology. According to the industry distribution chart, Coherus Oncology ranks #999999 out of 401 companies in the Biotechnology industry.
Is Coherus Oncology's EV-to-EBITDA too high?
Coherus Oncology's current EV-to-EBITDA is -0.96. Based on the distribution chart, Coherus Oncology ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coherus Oncology has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's EV-to-EBITDA compare to NAUT and AVXL?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #999999 out of 401 companies for EV-to-EBITDA. This places Coherus Oncology in the lower half of its industry. The industry median EV-to-EBITDA is 13.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.60, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Coherus Oncology. For the Biotechnology industry, the median EV-to-EBITDA is 13.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current EV-to-EBITDA is -0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.80, compared to a current price of €1.03 — trading 28.8% above its estimated fair value. The current EV-to-EBITDA is -0.96. Coherus Oncology's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current EV-to-EBITDA is -0.96 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.03 is trading 28.8% above its estimated GF Value™ of €0.80.
GuruFocus considers Coherus Oncology to be Modestly Overvalued.
Key valuation signals for FRA:8C5:
EV-to-EBITDA: -0.96
GF Value™: €0.80 vs. price of €1.03 (28.8% above fair value)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
61GF Score
Get the complete analysis for FRA:8C5
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
